Myocarditis temporally related to the use of gefitinib (Iressa).
Gefitinib is a new drug that was approved by the US Food and Drug Administration in May 2003 for non-small cell cancer of the lung refractory to first- and second-line therapy. It is regarded as a rather safe drug with common adverse effects that include nausea, vomiting, diarrhea, rash, acne, and dry skin. However, it was reported in Japan to be associated with interstitial pneumonitis (2%-3% of subjects), presumably as a manifestation of a hypersensitivity reaction. The Food and Drug Administration studied this in US patients and found only a 0.3% occurrence and a slightly less than 0.1% mortality due to interstitial pneumonitis. To our knowledge, there has not been an association with fulminant myocarditis or acute myocarditis. We report the case of a 71-year-old man who died as a result of fulminant myocarditis 1 week after starting to take this new class of agent, gefitinib. On the basis of his medical history and our findings, we feel it necessary to consider hypersensitivity myocarditis related to gefitinib the probable cause of death.
Truell
Jeff S
JS
Department of Pathology and Laboratory Medicine, David Geffen School of Medicine, University of California-Los Angeles, CA 90095, USA. jtruell@ucla.edu
Fishbein
Michael C
MC
Figlin
Robert
R
D000208:Acute Disease; D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects*; D004342:Drug Hypersensitivity / Q000209:etiology* / Q000473:pathology; D017809:Fatal Outcome; D000077156:Gefitinib; D006801:Humans; D008297:Male; D009205:Myocarditis / Q000139:chemically induced* / Q000473:pathology; D032383:Myocytes, Cardiac / Q000473:pathology; D009336:Necrosis; D011799:Quinazolines / Q000009:adverse effects*
D000970:Antineoplastic Agents; D011799:Quinazolines; D000077156:Gefitinib